189 related articles for article (PubMed ID: 28632937)
1. Synthesis, biological evaluation and docking studies of trans-stilbene methylthio derivatives as cytochromes P450 family 1 inhibitors.
Wierzchowski M; Dutkiewicz Z; Gielara-Korzańska A; Korzański A; Teubert A; Teżyk A; Stefański T; Baer-Dubowska W; Mikstacka R
Chem Biol Drug Des; 2017 Dec; 90(6):1226-1236. PubMed ID: 28632937
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and evaluation of the inhibitory selectivity of novel trans-resveratrol analogues on human recombinant CYP1A1, CYP1A2 and CYP1B1.
Mikstacka R; Rimando AM; Dutkiewicz Z; Stefański T; Sobiak S
Bioorg Med Chem; 2012 Sep; 20(17):5117-26. PubMed ID: 22863525
[TBL] [Abstract][Full Text] [Related]
3. Thiomethylstilbenes as inhibitors of CYP1A1, CYP1A2 and CYP1B1 activities.
Mikstacka R; Baer-Dubowska W; Wieczorek M; Sobiak S
Mol Nutr Food Res; 2008 Jun; 52 Suppl 1():S77-83. PubMed ID: 18435436
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of human CYP1 enzymes by a classical inhibitor α-naphthoflavone and a novel inhibitor N-(3, 5-dichlorophenyl)cyclopropanecarboxamide: An in vitro and in silico study.
Juvonen RO; Jokinen EM; Javaid A; Lehtonen M; Raunio H; Pentikäinen OT
Chem Biol Drug Des; 2020 May; 95(5):520-533. PubMed ID: 32060993
[TBL] [Abstract][Full Text] [Related]
5. Candidate cytochrome P450 genes for ethoxyresorufin O-deethylase activity in oyster Crassostrea gigas.
Siebert MN; Mattos JJ; Toledo-Silva G; Razzera G; Bainy ACD
Aquat Toxicol; 2017 Aug; 189():142-149. PubMed ID: 28623690
[TBL] [Abstract][Full Text] [Related]
6. Characterization of differences in substrate specificity among CYP1A1, CYP1A2 and CYP1B1: an integrated approach employing molecular docking and molecular dynamics simulations.
Kesharwani SS; Nandekar PP; Pragyan P; Rathod V; Sangamwar AT
J Mol Recognit; 2016 Aug; 29(8):370-90. PubMed ID: 26916064
[TBL] [Abstract][Full Text] [Related]
7. Hydration and Structural Adaptations of the Human CYP1A1, CYP1A2, and CYP1B1 Active Sites by Molecular Dynamics Simulations.
Dutkiewicz Z; Mikstacka R
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511239
[TBL] [Abstract][Full Text] [Related]
8. Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2.
Chang TK; Chen J; Lee WB
J Pharmacol Exp Ther; 2001 Dec; 299(3):874-82. PubMed ID: 11714871
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of human recombinant cytochromes P450 CYP1A1 and CYP1B1 by trans-resveratrol methyl ethers.
Mikstacka R; Przybylska D; Rimando AM; Baer-Dubowska W
Mol Nutr Food Res; 2007 May; 51(5):517-24. PubMed ID: 17440990
[TBL] [Abstract][Full Text] [Related]
10. Theoretical investigation of differences in nitroreduction of aristolochic acid I by cytochromes P450 1A1, 1A2 and 1B1.
Jerabek P; Martinek V; Stiborova M
Neuro Endocrinol Lett; 2012; 33 Suppl 3():25-32. PubMed ID: 23353840
[TBL] [Abstract][Full Text] [Related]
11. Metabolic activation of polycyclic aromatic hydrocarbons and other procarcinogens by cytochromes P450 1A1 and P450 1B1 allelic variants and other human cytochromes P450 in Salmonella typhimurium NM2009.
Shimada T; Oda Y; Gillam EM; Guengerich FP; Inoue K
Drug Metab Dispos; 2001 Sep; 29(9):1176-82. PubMed ID: 11502724
[TBL] [Abstract][Full Text] [Related]
12. Nitidine Chloride-Induced CYP1 Enzyme Inhibition and Alteration of Estradiol Metabolism.
Mao X; Wang J; Wang Q; Yang L; Li Y; Lin H; Peng Y; Zheng J
Drug Metab Dispos; 2019 Aug; 47(8):919-927. PubMed ID: 31147316
[TBL] [Abstract][Full Text] [Related]
13. Molecular modelling of CYP1 family enzymes CYP1A1, CYP1A2, CYP1A6 and CYP1B1 based on sequence homology with CYP102.
Lewis DF; Lake BG; George SG; Dickins M; Eddershaw PJ; Tarbit MH; Beresford AP; Goldfarb PS; Guengerich FP
Toxicology; 1999 Nov; 139(1-2):53-79. PubMed ID: 10614688
[TBL] [Abstract][Full Text] [Related]
14. Induction of CYP1A1, CYP1A2, and CYP1B1 mRNAs by nitropolycyclic aromatic hydrocarbons in various human tissue-derived cells: chemical-, cytochrome P450 isoform-, and cell-specific differences.
Iwanari M; Nakajima M; Kizu R; Hayakawa K; Yokoi T
Arch Toxicol; 2002 Jun; 76(5-6):287-98. PubMed ID: 12107646
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of procarcinogen-bioactivating human CYP1A1, CYP1A2 and CYP1B1 enzymes by melatonin.
Chang TK; Chen J; Yang G; Yeung EY
J Pineal Res; 2010 Jan; 48(1):55-64. PubMed ID: 19919601
[TBL] [Abstract][Full Text] [Related]
16. Cytochrome P450 CYP1 metabolism of hydroxylated flavones and flavonols: Selective bioactivation of luteolin in breast cancer cells.
Wilsher NE; Arroo RR; Matsoukas MT; Tsatsakis AM; Spandidos DA; Androutsopoulos VP
Food Chem Toxicol; 2017 Dec; 110():383-394. PubMed ID: 29097115
[TBL] [Abstract][Full Text] [Related]
17. Biological roles of cytochrome P450 1A1, 1A2, and 1B1 enzymes.
Kwon YJ; Shin S; Chun YJ
Arch Pharm Res; 2021 Jan; 44(1):63-83. PubMed ID: 33484438
[TBL] [Abstract][Full Text] [Related]
18. Effect of natural analogues of trans-resveratrol on cytochromes P4501A2 and 2E1 catalytic activities.
Mikstacka R; Rimando AM; Szalaty K; Stasik K; Baer-Dubowska W
Xenobiotica; 2006 Apr; 36(4):269-85. PubMed ID: 16684708
[TBL] [Abstract][Full Text] [Related]
19. Predicting drug metabolism by CYP1A1, CYP1A2, and CYP1B1: insights from MetaSite, molecular docking and quantum chemical calculations.
Pragyan P; Kesharwani SS; Nandekar PP; Rathod V; Sangamwar AT
Mol Divers; 2014 Nov; 18(4):865-78. PubMed ID: 25028215
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of CYP1 by berberine, palmatine, and jatrorrhizine: selectivity, kinetic characterization, and molecular modeling.
Lo SN; Chang YP; Tsai KC; Chang CY; Wu TS; Ueng YF
Toxicol Appl Pharmacol; 2013 Nov; 272(3):671-80. PubMed ID: 23886934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
